48 related articles for article (PubMed ID: 37506533)
1. Therapeutic Challenges in Patients with Gynecologic Carcinosarcomas: Analysis of a Multicenter National Cohort Study from the French Prospective TMRG Network.
Romeo C; Le Saux O; Jacobs M; Joly F; Ferron G; Favier L; Fumet JD; Isambert N; Colombo PE; Sabatier R; Bastide L; Charreton A; Devouassoux-Shisheboran M; Gertych W; Dubot C; Bello Roufai D; Bataillon G; Berton D; Kalbacher E; Pautier P; Pomel C; Cornou C; Treilleux I; Lardy-Cleaud A; Ray-Coquard I
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053517
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic strategies targeting folate receptor α for ovarian cancer.
Mai J; Wu L; Yang L; Sun T; Liu X; Yin R; Jiang Y; Li J; Li Q
Front Immunol; 2023; 14():1254532. PubMed ID: 37711615
[TBL] [Abstract][Full Text] [Related]
3. Folate receptor alpha protein expression in ovarian serous cystadenocarcinoma tumors of The Cancer Genome Atlas: exploration beyond single-agent therapy.
Persenaire C; Bitler BG; Corr BR
medRxiv; 2024 Apr; ():. PubMed ID: 38645083
[TBL] [Abstract][Full Text] [Related]
4. Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients.
Norton N; Youssef B; Hillman DW; Nassar A; Geiger XJ; Necela BM; Liu H; Ruddy KJ; Polley MC; Ingle JN; Couch FJ; Perez EA; Liu MC; Carter JM; Leon-Ferre RA; Boughey JC; Somers EB; Kalari KR; Visscher DW; Goetz MP; Knutson KL
NPJ Breast Cancer; 2020; 6():4. PubMed ID: 32047850
[TBL] [Abstract][Full Text] [Related]
5. Sensitivity and specificity of folate receptor α-positive circulating tumour cells in gastric cancer.
Cao B; Liu L; Zhang R; Dong H; Shen J
Postgrad Med J; 2024 Jan; 100(1180):112-119. PubMed ID: 37973392
[TBL] [Abstract][Full Text] [Related]
6. Case Report: Niraparib as Maintenance Therapy in A Patient With Ovarian Carcinosarcoma.
Zhang JQ; Zhao BB; Wang MM; Li L
Front Oncol; 2021; 11():603591. PubMed ID: 34938651
[TBL] [Abstract][Full Text] [Related]
7. Development of an FRα Companion Diagnostic Immunohistochemical Assay for Mirvetuximab Soravtansine.
James RL; Sisserson T; Cai Z; Dumas ME; Inge LJ; Ranger-Moore J; Mason A; Sloss CM; McArthur K
Arch Pathol Lab Med; 2024 Jan; ():. PubMed ID: 38282564
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of stage IVB ovarian carcinosarcoma with PARP Inhibitor: A case report.
St Laurent JD; Abel MK; Liu J; Quade BJ; Davis MR
Gynecol Oncol Rep; 2024 Feb; 51():101322. PubMed ID: 38273934
[TBL] [Abstract][Full Text] [Related]
9. Is minimally invasive radical surgery safe for patients with cervical cancer ≤2 cm in size? (MISAFE): Gynecologic Oncology Research Investigators coLLborAtion study (GORILLA-1003).
Kong TW; Kim J; Son JH; Lee AJ; Yang EJ; Shim SH; Kim NK; Kim Y; Suh DH; Hwang DW; Park SJ; Kim HS; Lee YY; Yoo JG; Lee SJ; Chang SJ
Gynecol Oncol; 2023 Sep; 176():122-129. PubMed ID: 37515926
[TBL] [Abstract][Full Text] [Related]
10. The impact of the distance traveled between residence and gestational trophoblastic neoplasia reference center and clinical outcomes in Brazilian women.
Braga A; Lopes R; Campos V; Freitas F; Maestá I; Sun SY; Pedrotti LG; Bessel M; de Sousa CB; Leal E; Yela D; Uberti E; Madi JM; Viggiano M; Junior JA; Filho JR; Elias KM; Horowitz NS; Berkowitz RS
Gynecol Oncol; 2023 Sep; 176():130-138. PubMed ID: 37524011
[TBL] [Abstract][Full Text] [Related]
11. Conservative surgical approaches for small volume FIGO stage IB1 cervical cancer. Updated survival and obstetric outcomes of an expanded cohort.
Korompelis P; Rundle S; Cassar V; Ratnavelu N; Ralte A; Biliatis I; Kucukmetin A
Gynecol Oncol; 2023 Sep; 176():155-161. PubMed ID: 37542842
[TBL] [Abstract][Full Text] [Related]
12. Extensive versus focal lymphovascular invasion in squamous cell carcinoma of the cervix: A comprehensive international, multicenter, retrospective clinicopathologic study.
Praiss AM; Allison D; Tessier-Cloutier B; Flynn J; Iasonos A; Hoang L; Patrichi A; Terinte C; Pesci A; Mateoiu C; Lastra RR; Puscasiu L; Kiyokawa T; Ali-Fehmi R; Kheil M; Oliva E; Devins KM; Abu-Rustum NR; Soslow RA; Stolnicu S
Gynecol Oncol; 2023 Sep; 176():147-154. PubMed ID: 37541128
[TBL] [Abstract][Full Text] [Related]
13. A putative role for ALDH inhibitors and chemoprevention of BRCA-mutation-driven tumors.
McGonigal S; Wu R; Grimley E; Turk EG; Zhai Y; Cho KR; Buckanovich RJ
Gynecol Oncol; 2023 Sep; 176():139-146. PubMed ID: 37535994
[TBL] [Abstract][Full Text] [Related]
14. Vulvar cancer survival by primary treatment modality: A retrospective cohort study.
Bruce KH; Alabaster A; Tran AM
Gynecol Oncol; 2023 Sep; 176():173-178. PubMed ID: 37562168
[TBL] [Abstract][Full Text] [Related]
15. Drug-induced interstitial lung disease caused by olaparib: three case reports and review of the Japanese Adverse Drug Event Report database and literature.
Ishimoto H; Sakamoto N; Kido T; Ozasa M; Tsutsui S; Mori M; Setoguchi D; Takemoto S; Obase Y; Ishimatsu Y; Tomonaga C; Matsumoto K; Morisaki S; Miura K; Mukae H
BMC Pulm Med; 2023 Aug; 23(1):289. PubMed ID: 37553592
[TBL] [Abstract][Full Text] [Related]
16. Folate receptor alpha is widely expressed and a potential therapeutic target in uterine and ovarian carcinosarcoma.
Saito A; Nishikawa T; Yoshida H; Mizoguchi C; Kitadai R; Yamamoto K; Yazaki S; Kojima Y; Ishikawa M; Kato T; Yonemori K
Gynecol Oncol; 2023 Sep; 176():115-121. PubMed ID: 37506533
[TBL] [Abstract][Full Text] [Related]
17. Mesothelin expression in gynecologic carcinosarcoma: clinicopathological significance and correlation with HER2 expression.
Kitadai R; Nishikawa T; Yoshida H; Mizoguchi C; Yamamoto K; Kato T; Yonemori K
J Gynecol Oncol; 2024 Mar; 35(2):e11. PubMed ID: 37914528
[TBL] [Abstract][Full Text] [Related]
18. Racial disparities in uterine and ovarian carcinosarcoma: A population-based analysis of treatment and survival.
Rojas C; Tian C; Powell MA; Chan JK; Bateman NW; Conrads TP; Rocconi RP; Jones NL; Shriver CD; Hamilton CA; Maxwell GL; Casablanca Y; Darcy KM
Gynecol Oncol; 2020 Apr; 157(1):67-77. PubMed ID: 32029291
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
